Cabot Corporation

NYSE:CBT

Chemicals - Specialty

Basic Materials
$74.03 +1.09%

+$0.96 today

Market cap
$3.80B
Beta
0.83
P/E (TTM)
16.3
EPS (TTM)
$5.48
Dividend yield
2.04%
52W Low $58.33High $90.08

Volume 0.53M

Average 0.43M

CBT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Cabot CorporationNYSE: CBT

EBITDA · Q3 FY2026 · quarter ended Jun 2026

EBITDA declines year over year

Q3 FY2026 EBITDA of $148M fell 30.5% year over year, behind the -14.9% change in trailing-twelve-month EBITDA. Sequentially, it fell 22.1% from the prior quarter. Over 3 fiscal years it compounded at +13.9% a year.

Context

  • EBITDA amounted to 21.4% of revenue in FY2025, up 2.3 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of $758.47M (-4.5%) for the fiscal year ending Sep 2026, a slowdown from the +4.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$148M-22.1% QoQ
Last fiscal yearSep 2025
$794M+4.3% YoY
LTMJun 2026
$690M-14.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.5%+8.8%+39.3 pp
1 year+4.3%-4.5%-8.8 pp
3-year CAGR+13.9%+2.5%-11.4 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
794M USD
Year-over-year change
+4.3%
4-year CAGR
+6.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CBT compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -14.9% is the 10th highest of 11, against a peer median of +12.4%.
  • EBITDA amounts to 19.0% of revenue for CBT, versus a peer median of 16.7%.
CBT Competitors
EBITDA for CBT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SSLSasol LimitedFY2026ZAR 69.09B ZAR+94.0%+0.6%25.9%
MEOHMethanex CorporationLTM Jun 2026$1.01B USD+3.8%-7.1%23.6%
CBTCabot CorporationLTM Jun 2026$690M USD-14.9%+13.9%19.0%
FULH.B. Fuller CompanyLTM Aug 2026$540.79M USD+11.0%+2.4%15.2%
AVNTAvient CorporationLTM Sep 2026$506.9M USD+19.1%+16.5%14.8%
KNFKnife River CorporationLTM Jun 2026$493.68M USD+14.9%+16.8%14.9%
CECelanese CorporationLTM Jun 2026$385M USD+49.2%-47.4%4.0%
SXTSensient Technologies CorporationLTM Jun 2026$301.51M USD+13.9%+2.5%17.7%
HWKNHawkins, Inc.LTM Sep 2026$183.41M USD+8.8%+15.0%16.1%
WDFCWD-40 CompanyLTM Aug 2026$119.43M USD+5.4%+6.5%17.4%
PRMPerimeter Solutions, Inc.LTM Jun 2026-$300.15M USD-303.2%—39.6%
Peer median (excluding CBT) —+12.4%+2.5%16.7%

Competitors are the stored peer set for CBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue3.41B4.32B3.93B3.99B3.71B
Cost of Revenue2.61B3.44B3.09B3.03B2.77B
Gross Profit799M885M839M960M940M
Gross Margin23.4%20.5%21.3%24.0%25.3%
Research & Development56M55M57M63M59M
Selling, General & Admin289M258M253M283M260M
Operating Expenses345M496M313M346M319M
Depreciation & Amortization160M146M144M151M154M
EBITDA615M537M685M761M794M
EBITDA Margin18.0%12.4%17.4%19.1%21.4%
Operating Income454M389M526M614M621M
Operating Margin13.3%9.0%13.4%15.4%16.7%
Interest Income8M11M31M32M27M
Interest Expense49M56M90M81M76M
Other Income / Expenses(45M)(44M)(70M)(79M)(49M)
Income Before Tax409M345M456M535M572M
Pre-Tax Margin12.0%8.0%11.6%13.4%15.4%
Income Tax Expense123M102M(28M)111M196M
Net Income250M209M445M380M331M
Net Margin7.3%4.8%11.3%9.5%8.9%
EPS (Basic)4.363.657.796.796.07
EPS (Diluted)4.343.627.736.726.02
Weighted Avg Shares56.73M56.25M55.24M54.3M53.7M
Weighted Avg Shares (Diluted)56.8M56.9M56.5M55.7M54.2M

Cabot Corporation

NYSE:CBT

Intrinsic Alpha fair value

Locked

Current Price

$74.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.